MPT64 secretion as a viability-associated immunoassay readout for rapid phenotypic drug susceptibility classification of Mycobacterium tuberculosis : a proof-of-concept study
Yoshiro Murase, Rikiya Takeuchi, Yoshiharu Ohtaki, Makiko Hosoya, Akio Aono, Kinuyo Chikamatsu, Yuta Morishige, Yuriko Igarashi, Joseph Edwin L Bascuña, Gel Anne Marie V Atienza, Angeline Grace A Sedusta, Catherine Ann P L Sacopon, Ramón P Basilio, Midori Kato-Maeda, Satoshi Mitarai
Source abstract
Abstract Objectives To evaluate MPT64 secretion as a viability-associated readout for rapid phenotypic drug susceptibility testing (pDST) of Mycobacterium tuberculosis. Methods We evaluated MPT64-pDST in 130 M. tuberculosis strains: clinical isolates, WHO quality assessment strains and in vitro-selected resistant mutants (for linezolid only). We assessed the diagnostic performance of MPT64-pDST for determining susceptibility to rifampicin, isoniazid and moxifloxacin. As a secondary objective, we explored its performance for linezolid and bedaquiline. MPT64 was quantified by chemiluminescent enzyme immunoassay, and susceptibility was inferred from Log2 fold change relative to drug-free controls. Reference standards were minimum inhibitory concentration testing for rifampicin, isoniazid, linezolid and bedaquiline and MGIT-based DST for moxifloxacin. Performance was evaluated using receiver operating characteristic analysis, full-dataset Youden-optimal candidate cutoffs and 2000-iteration stratified bootstrap out-of-bag (OOB) internal validation. Results Using drug-specific full-dataset Youden-optimal candidate cutoffs, MPT64-pDST showed high categorical agreement with reference DST, with no false-resistant classifications for rifampicin, isoniazid or moxifloxacin. Resistance-detection sensitivity was 100% for rifampicin, 98% for isoniazid and 90% for moxifloxacin, and out-of-bag bootstrap estimates were comparable to the full-dataset estimates. Exploratory analyses for linezolid demonstrated separation between susceptible and resistant mutants. The single bedaquiline-resistant isolate was clearly distinguishable from 39 bedaquiline-susceptible isolates. Conclusions These findings provide proof of concept that the immunoassay-based MPT64-pDST can enable rapid phenotypic susceptibility classification for rifampicin, isoniazid and moxifloxacin. Further validation in larger isolate collections, including isolates with borderline phenotypes, is warranted.
Evidence graph
No public relationships recorded yet.
Integrity note: This page is a factual metadata record created by deterministic ingestion. It is not a claim that the work moves a mathematical frontier or has been independently verified.